Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New therapies, new concerns: rituximab-associated lung injury.

Literature DB >> 20195643

New therapies, new concerns: rituximab-associated lung injury.

Larry C Lands.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2010 PMID： 20195643 DOI： 10.1007/s00467-010-1476-3

Source DB: PubMed Journal: Pediatr Nephrol ISSN： 0931-041X Impact factor: 3.714

× No keyword cloud information.

15 in total

1. Pharmacodynamics of rituximab in kidney allotransplantation.

Authors: H Genberg; A Hansson; A Wernerson; L Wennberg; G Tydén
Journal: Am J Transplant Date: 2006-08-21 Impact factor: 8.086

Review 2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Authors: Robert Marcus; Anton Hagenbeek
Journal: Eur J Haematol Suppl Date: 2007-01

3. Severe respiratory adverse events associated with rituximab infusion.

Authors: Koichi Kamei; Shuichi Ito; Kazumoto Iijima
Journal: Pediatr Nephrol Date: 2009-12-19 Impact factor: 3.714

4. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.

Authors: Martin Bitzan; Jodie D Ouahed; Lucy Carpineta; Chantal Bernard; Lorraine E Bell
Journal: Pediatr Nephrol Date: 2010-02-06 Impact factor: 3.714

Review 5. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.

Authors: F Goldblatt; D A Isenberg
Journal: Handb Exp Pharmacol Date: 2008

6. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.

Authors: Dimitrios Kalkanis; Alexandra Stefanovic; Fabio Paes; Maricer P Escalon; Aldo Serafini; Izidore S Lossos
Journal: Leuk Lymphoma Date: 2009-06

Review 7. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature.

Authors: Gustavo A Heresi; Carol F Farver; James K Stoller
Journal: Respiration Date: 2007-06-27 Impact factor: 3.580

Review 8. Rituximab-induced interstitial lung disease.

Authors: Stephanie A Wagner; Apurva C Mehta; Damian A Laber
Journal: Am J Hematol Date: 2007-10 Impact factor: 10.047

9. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.

Authors: Xin Liu; Xiao-Nan Hong; Ya-Jia Gu; Bi-Yun Wang; Zhi-Guo Luo; Junning Cao
Journal: Leuk Lymphoma Date: 2008-09

Review 10. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

Authors: Martin Bitzan; Mark Anselmo; Lucy Carpineta
Journal: Pediatr Pulmonol Date: 2009-09

9 in total

Review 1. Design of smart HPMA copolymer-based nanomedicines.

Authors: Jiyuan Yang; Jindřich Kopeček
Journal: J Control Release Date: 2015-10-03 Impact factor: 9.776

2. Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines.

Authors: Te-Wei Chu; Jindřich Kopeček
Journal: Biomater Sci Date: 2015-07 Impact factor: 6.843

3. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.

Authors: Ashima Gulati; Aditi Sinha; Stanley C Jordan; Pankaj Hari; Amit K Dinda; Sonika Sharma; Rajendra N Srivastava; Asha Moudgil; Arvind Bagga
Journal: Clin J Am Soc Nephrol Date: 2010-08-26 Impact factor: 8.237

4. Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells.

Authors: Libin Zhang; Yixin Fang; Jiyuan Yang; Jindřich Kopeček
Journal: J Control Release Date: 2016-12-24 Impact factor: 9.776

5. Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model.

Authors: Jiawei Wang; Yachao Li; Lian Li; Jiyuan Yang; Jindřich Kopeček
Journal: Macromol Biosci Date: 2020-03-20 Impact factor: 4.979